<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02385019</url>
  </required_header>
  <id_info>
    <org_study_id>TREGeneration-Portugal</org_study_id>
    <nct_id>NCT02385019</nct_id>
  </id_info>
  <brief_title>A Phase 1/2 Trial of Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-Host-Disease</brief_title>
  <acronym>TREGeneration</acronym>
  <official_title>A Phase 1/2 Trial of Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-Host-Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Medicina Molecular João Lobo Antunes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital de Santa Maria, Portugal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IPOFG Lisboa, Portugal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IPOFG Porto, Portugal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto de Medicina Molecular João Lobo Antunes</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1/2 clinical study for the treatment of steroid-refractory chronic graft versus host
      disease after an allogeneic transplant of hematopoietic progenitors with donor
      CliniMACS-selected regulatory T cells
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1/2 clinical study evaluating safety (Phase 1) and preliminary efficacy (Phase 2) of
      donor regulatory T cells for patients with steroid-refractory chronic graft versus host
      disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).

      Patients must have persistent signs and symptoms despite the use of prednisone or equivalent
      at ≥ 0.25 mg/kg/day (or 0.5 mg/kg every other day), for at least 4 weeks without complete
      resolution of signs and symptoms. Occasional patients requiring lower doses of prednisone
      will be eligible if associated with other immunosuppressive drugs.

      Phase 1 clinical trial will include groups of 5 patients sequentially treated with: 0.5 x
      10ˆ6, 1.0 x 10ˆ6, 2-3 x 10ˆ6 donor Treg/kg. Phase 2 clinical trial will include another 5 to
      10 patients treated with MTD.

      Donor Treg will be selected by the following sequential steps:

        1. - negative depletion of CD8 and CD19 cells

        2. - positive selection of CD25 cells
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression of graft versus host disease according to the 2014 NIH consensus criteria and myelosuppression after the administration of 3 doses of donor regulatory T cells / kg recipient's body weight: 0.5 x 10ˆ6, 1.0 x 10ˆ6 and 2.0-3.0 x 10ˆ6 cells</measure>
    <time_frame>Response evaluated 12 weeks after infusion</time_frame>
    <description>Progression of graft versus host disease and myelosuppression are indicators of toxicity and MTD associated with the infusion of donor regulatory T cells</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chronic graft versus host disease improvement according to the 2014 NIH consensus criteria following the infusion of donor regulatory T cells</measure>
    <time_frame>Response evaluated 12 weeks after infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total lymphocyte, CD4, CD8 and regulatory T cell counts after the infusion of donor regulatory T cells for the treatment of chronic graft versus host disease</measure>
    <time_frame>Response evaluated 12 weeks after infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival at 1 year after administration of donor regulatory T cells in patients with chronic graft versus host disease</measure>
    <time_frame>Response evaluated 12 months after infusion</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Graft vs Host Disease</condition>
  <arm_group>
    <arm_group_label>Administration of 0.5 x 10ˆ6 donor Treg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First group of 5 patients will receive a total of 0.5 x 10ˆ6 donor Treg/kg. Part of Phase 1 study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Administration of 1.0 x 10ˆ6 donor Treg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Second group of 5 patients will receive a total of 1.0 x 10ˆ6 donor Treg/kg. Part of Phase 1 study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Administration of 2.0-3.0 x 10ˆ6 donor Treg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Third group of 5 patients will receive a total of 2.0-3.0 x 10ˆ6 donor Treg/kg. Part of Phase 1 study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Administration of MTD of donor T reg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preliminary Phase 2 study will include another 5 to 10 patients at the MTD identified in the Phase 1 study</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Donor regulatory T cell adoptive immunotherapy in chronic graft versus host disease</intervention_name>
    <description>Regulatory T cells selected by a sequential 2 step procedure:
- Negative selection of CD8 and CD19 cells
- Positive selection of CD25 cells</description>
    <arm_group_label>Administration of 0.5 x 10ˆ6 donor Treg/kg</arm_group_label>
    <arm_group_label>Administration of 1.0 x 10ˆ6 donor Treg/kg</arm_group_label>
    <arm_group_label>Administration of 2.0-3.0 x 10ˆ6 donor Treg/kg</arm_group_label>
    <arm_group_label>Administration of MTD of donor T reg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must have persistent signs and symptoms despite the use of prednisone or
             equivalent at ≥ 0.25 mg/kg/day (or 0.5 mg/kg every other day), for at least 4 weeks
             without complete resolution of signs and symptoms. Occasional patients requiring lower
             doses of prednisone will be eligible if associated with other immunosuppressive drugs.

          2. Stable immunosuppressive medication in the 4 weeks prior to initiation of treatment

          3. PS 0-2 ECOG

          4. Adequate liver, kidney, lung and hematopoietic system functions

        Exclusion Criteria:

          1. Pediatric patients

          2. Pregnant women

          3. Ongoing prednisone requirement &gt;1 mg/kg/day (or equivalent)

          4. Concurrent use of calcineurin-inhibitor plus sirolimus (either agent alone is
             acceptable)

          5. New immunosuppressive medication in the 4 weeks prior

          6. Extra-corporeal Photopheresis or rituximab therapy in the 4 weeks prior

          7. Exposure to T-cell or IL-2 targeted medication (e.g. ATG, alemtuzumab, basiliximab,
             denileukin diftitox) within 100 days prior

          8. Donor lymphocyte infusion within 100 days prior

          9. Active malignant relapse

         10. Active uncontrolled infection

         11. HIV-infected patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Instituto Portugues de Oncologia</name>
      <address>
        <city>Lisboa</city>
        <zip>1099-023</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelina Ferreira, MD</last_name>
      <phone>+351917502335</phone>
      <email>iferreira@ipolisboa.min-saude.pt</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Santa Maria, Faculdade de Medicina da Universidade de Lisboa, Instituto de Medicina Molecular</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-028</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joao F Lacerda, MD PhD</last_name>
      <phone>+351919727656</phone>
      <email>jlacerda@fm.ul.pt</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Portugues de Oncologia</name>
      <address>
        <city>Porto</city>
        <zip>4200-072</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Pinho Vaz, MD</last_name>
      <phone>+351968014520</phone>
      <email>cpvaz@ipoporto.min-saude.pt</email>
    </contact>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2015</study_first_submitted>
  <study_first_submitted_qc>March 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2015</study_first_posted>
  <last_update_submitted>March 4, 2018</last_update_submitted>
  <last_update_submitted_qc>March 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto de Medicina Molecular João Lobo Antunes</investigator_affiliation>
    <investigator_full_name>Joao F. Lacerda</investigator_full_name>
    <investigator_title>MD PhD, Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Allogeneic hematopoietic stem cell transplantation</keyword>
  <keyword>Graft vs host disease</keyword>
  <keyword>Regulatory T cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

